Axa’s PTC Therapeutics PTCT Stock Holding History

Axa’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-16,500	Closed	-$1.01M	–	1309
2020 Q4	$1.01M	Hold	16,500	–	–	﹤0.01%	973
2020 Q3	$771K	Sell	16,500 -300	-2%	-$14.8K	﹤0.01%	977
2020 Q2	$852K	Buy	+16,800	New	+$825K	﹤0.01%	980
2018 Q1	–	Sell	-68,700	Closed	-$1.15M	–	1411
2017 Q4	$1.15M	Sell	68,700 -64,700	-49%	-$1.1M	﹤0.01%	972
2017 Q3	$2.67M	Sell	133,400 -28,200	-17%	-$552K	0.01%	768
2017 Q2	$2.96M	Buy	161,600 +151,100	+1,439%	+$2.04M	0.01%	714
2017 Q1	$103K	Buy	+10,500	New	+$127K	﹤0.01%	1252
2015 Q4	–	Sell	-69,581	Closed	-$1.86M	–	1468
2015 Q3	$1.86M	Sell	69,581 -1,472	-2%	-$63K	0.01%	784
2015 Q2	$3.42M	Hold	71,053	–	–	0.01%	670
2015 Q1	$4.32M	Buy	71,053 +5,017	+8%	+$306K	0.02%	639
2014 Q4	$3.42M	Buy	66,036 +4,226	+7%	+$186K	0.01%	661
2014 Q3	$2.72M	Hold	61,810	–	–	0.01%	670
2014 Q2	$1.62M	Buy	+61,810	New	+$1.32M	0.01%	825

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Axa's PTCT Position: Q1 2021 in Review

Axa sold out of PTC Therapeutics (PTCT) in Q1 2021, closing a stake of 16,500 shares — an estimated $1.01M sold.

Axa first reported a position in PTCT in Q2 2014 and held it in 13 quarters. The position peaked at $4.32M in Q1 2015. 207 funds tracked by Wall St. Rank hold PTCT as of Q1 2021.

Axa reported no remaining PTC Therapeutics position as of Q1 2021 after selling out during the quarter.
Axa sold 16,500 PTC Therapeutics shares in Q1 2021, an estimated $1.01M.
Axa first reported a position in PTC Therapeutics in Q2 2014 and held it in 13 quarters.
Axa's PTC Therapeutics position peaked at $4.32M in Q1 2015.
207 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.